Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial

<p>Supplementary Figure 4: Multivariate analysis. Baselines were MGMT = “methylated” and Classifier = “GBM MES”. Classifier assignment is based on the v12.5 version (n = 380).</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Tobias Kessler (17079209) (author)
Бусад зохиолчид:	Daniel Schrimpf (17079212) (author), Laura Doerner (17079215) (author), Ling Hai (17079218) (author), Leon D. Kaulen (17079221) (author), Jakob Ito (17079224) (author), Martin van den Bent (17079227) (author), Martin Taphoorn (17079230) (author), Alba A. Brandes (17079233) (author), Ahmed Idbaih (17079236) (author), Julien Dômont (17079239) (author), Paul M. Clement (15044256) (author), Mario Campone (15027156) (author), Martin Bendszus (17079242) (author), Andreas von Deimling (15037904) (author), Felix Sahm (15097382) (author), Michael Platten (15018165) (author), Wolfgang Wick (15018168) (author), Antje Wick (17079245) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Methods and Technology Biomarkers Epigenetic biomarkers Prognostic biomarkers CNS Cancers Gliomas, Glioblastomas Computational Methods Sequence analysis Precision Medicine
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
-н: Tobias Kessler (17079209)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
-н: Tobias Kessler (17079209)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
-н: Tobias Kessler (17079209)
Хэвлэсэн: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
-н: Tobias Kessler (17079209)
Хэвлэсэн: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
-н: Tobias Kessler (17079209)
Хэвлэсэн: (2025)

Supplementary Figure S7 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
-н: Tobias Kessler (17079209)
Хэвлэсэн: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
-н: Francesca Orzan (15055579)
Хэвлэсэн: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
-н: Francesca Orzan (15055579)
Хэвлэсэн: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
-н: Francesca Orzan (15055579)
Хэвлэсэн: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
-н: Defne Bayik (14961098)
Хэвлэсэн: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
-н: Qingsheng Xu (17078830)
Хэвлэсэн: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
-н: Qingsheng Xu (17078830)
Хэвлэсэн: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
-н: Bachchu Lal (17141949)
Хэвлэсэн: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
-н: Isha Mondal (16721699)
Хэвлэсэн: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
-н: Michael Kilian (16697663)
Хэвлэсэн: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
-н: Michael Kilian (16697663)
Хэвлэсэн: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
-н: Michael Kilian (16697663)
Хэвлэсэн: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
-н: Min Wu (14962986)
Хэвлэсэн: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
-н: Min Wu (14962986)
Хэвлэсэн: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
-н: Min Wu (14962986)
Хэвлэсэн: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
-н: Min Wu (14962986)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3bhlba0e9tbdeont88ikkosv8l